Salix Pharmaceuticals, Ltd.

397 articles about Salix Pharmaceuticals, Ltd.

• Salix And Alfasigma Will Initiate Late-Stage Program To Study Rifaximin In Patients With Postoperative Crohn's Disease

  10/29/2018

  Salix Pharmaceuticals, Ltd. announced it has entered into an amendment to its existing license agreement with Alfasigma S.p.A. ("Alfasigma") to initiate a late-stage clinical program to study an investigational formulation of rifaximin in patients with postoperative Crohn's disease, an area of unmet medical need.

• Salix to Present Clinical Data for XIFAXAN® (RIFAXIMIN) and PLENVU® at the American College of Gastroenterology Annual Meeting

  10/8/2018

  Salix Pharmaceuticals ("Salix"), one of the largest specialty pharmaceutical companies in the world committed to the prevention and treatment of gastrointestinal diseases and a wholly owned subsidiary of Bausch Health Companies Inc.

• Salix Resolves Legacy SEC Investigation With No Penalty

  9/28/2018

  Salix Pharmaceuticals, Ltd., one of the largest specialty pharmaceutical companies in the world committed to the prevention and treatment of gastrointestinal diseases, and its parent company, Bausch Health Companies Inc. (NYSE/TSX: BHC) ("Bausch Health"), today issued the following statement regarding the successful resolution of the legacy investigation with the Securities and Exchange Commission (SEC).

• Dova Pharmaceuticals and Salix Enter Into Exclusive Co-Promotion Agreement For DOPTELET® (Avatrombopag)

  9/27/2018

  Salix Sales Force to Promote First FDA-Approved Drug for Thrombocytopenia in Chronic Liver Disease Patients Scheduled to Undergo a Procedure

• US WorldMeds And Salix Pharmaceuticals To Highlight Clinical Data For Opioid Withdrawal Treatment LUCEMYRA™ (lofexidine) At 2018 PAINWeek Conference

  9/4/2018

  Product Theater, Three Posters and Oral Poster Presentation to be Featured

• US WorldMeds and Salix Announce U.S. Launch of LUCEMYRA™ (lofexidine) 0.18 Mg Tablets

  8/6/2018

  First and only FDA-approved, non-opioid medication indicated for mitigation of opioid withdrawal symptoms is now available for prescription

• Salix Expands Microbiome Research And Discovery Through Strategic Collaboration With Cedars-Sinai Medical Center

  8/3/2018

  Research Led by Dr. Mark Pimentel's Lab Will Explore the Role of the Microbiome in the Treatment of Gastrointestinal (GI) Disorders

• Strategic appointment expands Atlantic Healthcare executive team

  8/2/2018

  Atlantic Healthcare plc (Atlantic Healthcare), a specialist gastrointestinal (GI) pharmaceutical company, developing treatments for inflammatory bowel disease and other GI diseases, has appointed John Temperato as U.S. President and Chief Operating Officer, to lead the commercialisation programme of alicaforsen in the U.S.

• Salix To Highlight New Clinical Data During Digestive Disease Week

  5/31/2018

  Salix Pharmaceuticals will present new scientific data, including one podium presentation and eight posters evaluating investigative data on the safety and efficacy of XIFAXAN® (rifaximin) and PLENVU® (polyethylene glycol 3350, sodium ascorbate, sodium sulfate, ascorbic acid, sodium chloride and potassium chloride for oral solution) at Digestive Disease Week (DDW).

• 

  Approved! FDA gives Dova Pharma’s Doptelet a Thumbs Up

  5/22/2018

  Dova Pharmaceuticals announced that the U.S. Food and Drug Administration (FDA) approved its Doptelet (avatrombopag) to treat thrombocytopenia in adults with chronic liver disease scheduled to undergo a procedure.

• FDA Extends PDUFA Action Date for Salix Pharma's PLENVU

  2/9/2018

  The PDUFA action date has been extended to allow the FDA more time to review additional data that was recently provided at its request.

• Salix Announces Filing Acceptance For PLENVU Next Generation Bowel Cleansing Preparation For Colonoscopies

  6/29/2017

• Salix Announces The Publication Of A Study Evaluating The Safety And Efficacy Of UCERIS (Budesonide) Tablets For Induction Of Remission In Patients With Active Mild To Moderate Ulcerative Colitis Refractory To Mesalamine Therapy

  5/18/2017

• Salix Unveils 360-Degree Virtual Reality Experience To Evolve Medical Understanding About Irritable Bowel Syndrome

  5/3/2017

• Salix Unveils 360-Degree Virtual Reality Experience To Evolve Medical Understanding About Irritable Bowel Syndrome

  5/3/2017

• Valeant Corrects Misleading Report About Salix Investigation

  3/2/2017

• Valeant's Salix Beefs Up Workforce With 250 Sales Reps

  2/27/2017

• Valeant's $10 Billion Salix Deal With Takeda Falls Apart

  12/1/2016

• Cash-Strapped Valeant in Talks to Divest Salix to Takeda for as Much as $10 Billion

  11/2/2016

• Led by Founders of Salix, Atlantic Healthcare Locks in $24 Million Financing

  3/21/2016